Allegro Diagnostics later this year plans to begin marketing a microarray-based test for early-stage lung cancer, according to CEO Dan Rippy.
Allegro Diagnostics later this year plans to begin marketing a microarray-based test for early-stage lung cancer, according to CEO Dan Rippy.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.